DexCom, Inc. (NASDAQ:DXCM) EVP Richard Doubleday sold 2,016 shares of the business’s stock in a transaction dated Monday, March 25th. The shares were sold at an average price of $127.38, for a total value of $256,798.08. Following the completion of the transaction, the executive vice president now directly owns 72,570 shares of the company’s stock, valued at approximately $9,243,966.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.
DexCom stock traded up $2.91 during midday trading on Friday, reaching $114.29. The company’s stock had a trading volume of 1,528,462 shares, compared to its average volume of 1,536,126. DexCom, Inc. has a 52 week low of $72.04 and a 52 week high of $156.16. The company has a quick ratio of 7.32, a current ratio of 7.64 and a debt-to-equity ratio of 1.52. The stock has a market cap of $10.29 billion, a PE ratio of 380.97 and a beta of 0.75.
DexCom (NASDAQ:DXCM) last released its earnings results on Thursday, February 21st. The medical device company reported $0.54 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.16 by $0.38. The firm had revenue of $338.00 million for the quarter, compared to analysts’ expectations of $331.60 million. DexCom had a positive return on equity of 4.98% and a negative net margin of 12.32%. The business’s revenue for the quarter was up 52.9% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.10 earnings per share. As a group, analysts expect that DexCom, Inc. will post 0.46 earnings per share for the current year.
A number of research analysts recently commented on DXCM shares. Cowen boosted their price target on DexCom from $150.00 to $175.00 and gave the company an “outperform” rating in a research note on Friday, February 22nd. Morgan Stanley boosted their price target on DexCom from $135.00 to $160.00 and gave the company an “equal weight” rating in a research note on Monday, February 25th. Canaccord Genuity boosted their price target on DexCom from $140.00 to $160.00 and gave the company a “buy” rating in a research note on Friday, February 22nd. BidaskClub raised DexCom from a “hold” rating to a “buy” rating in a research note on Friday, December 28th. Finally, Piper Jaffray Companies lifted their target price on DexCom to $165.00 and gave the company an “overweight” rating in a research report on Wednesday, January 9th. Six research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $149.53.
COPYRIGHT VIOLATION WARNING: “DexCom, Inc. (DXCM) EVP Richard Doubleday Sells 2,016 Shares” was reported by Baseball Daily News and is the property of of Baseball Daily News. If you are accessing this article on another publication, it was copied illegally and republished in violation of US and international copyright and trademark legislation. The legal version of this article can be viewed at https://www.baseballdailydigest.com/news/2019/04/21/dexcom-inc-dxcm-evp-sells-256798-08-in-stock.html.
DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G6, a CGM system for diabetes management; DexCom G5 mobile CGM system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system.
Read More: What are convertible shares?
Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.